Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003283 · ClinicalTrials.gov registry record · Phase 2
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00003283 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 38 participants.
The verdict
NCT00003283, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of octreotide alone or with prednisone in treating patients with metastatic or recurrent thymoma.
Interventions
- DRUG prednisone
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 1998-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003283
The ClinicalTrials.gov registry entry for NCT00003283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prednisone is the first listed.
NCT00003283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003283 about?
NCT00003283 is a clinical study titled "Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of octreotide alone or with prednisone in treating patients with metastatic or recurrent thymoma.
What is the current status of trial NCT00003283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 1998-10-13.
What interventions are being tested in trial NCT00003283?
The interventions under investigation include: prednisone (DRUG), octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00003283?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.